Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept

Liu, Huan; Ma, Yue; Xu, Hong-Chang; Huang, Li-Ying; Zhai, Liying; Zhang, Xiao-Rong

doi:10.1080/02713683.2020.1781193

Cited by 8 publications

(6 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The visual improvement was related with the life quality of RVO patients, while the incidence of ME/NVG would lead to following repeated anti-VEGF treatment and potential vitrectomy. 2 , 28 In this study, it was found that visual activity improvement rate was lower in the RVO cases with OSA and it demonstrated that OSA might lead to a poor recovery of both anatomy and function of retina in RVO cases. ME was a key reason of vision loss in the RVO cases, while it was found that RVO was related a higher risk of ME incidence.…”

Section: Discussionmentioning

confidence: 64%

Obstructive Sleep Apnea is Related with the Risk of Retinal Vein Occlusion

Wan¹,

Wu²,

Lu³

et al. 2021

NSS

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 64%

Obstructive Sleep Apnea is Related with the Risk of Retinal Vein Occlusion

Wan¹,

Wu²,

Lu³

et al. 2021

NSS

View full text Add to dashboard Cite

“…Studies have shown that the rate of graft rejection following PKP depends on the patient's condition and related risk factors 1,2 . Corneal neovascularization (CNV) is one of the factors responsible for graft rejection, CNV is characterized by the outgrowth of blood vessels from the limbus, which causes loss of corneal transparency and even graft failure 2,12,13 .…”

Section: Discussionmentioning

confidence: 99%

“…Graft survival is closely related to the size of the graft, quality of the donor graft, severity of the preoperative and postoperative infections, surgical technique used, and postoperative complications such as CNV 13,16,17 . In our study, the graft survival rates at the one-year follow-up were signi cantly higher in the DLKP group than those in the PKP group ( p = 0.033).…”

Section: Discussionmentioning

confidence: 99%

Clinical Observation of Therapeutic Keratoplasties for Infectious Keratitis: A Retrospective Cohort Study

Zeng

Zhang

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: To investigate the therapeutic outcomes of two types of keratoplasties in patients with infectious keratitis.Methods: This retrospective cohort study enrolled 52 consecutive patients (52 eyes) with medically uncontrolled infectious keratitis who underwent deep lamellar keratoplasty (DLKP) (n=16 eyes) or penetrating keratoplasty (PKP) (n=36 eyes; 24 nonperforated ulcers; 12 perforated ulcers) with a follow-up of 12 to 36 months (mean follow-up duration: DLKP, 24.6 months; PKP: 25.7 months) between June 2014 and 2019 at the Department of Ophthalmology, The Third Hospital of Hebei Medical University. The clinical characteristics, preoperative, and postoperative best-corrected visual acuity (BCVA) outcomes, therapeutic success rate, graft rejection, management, and complications were assessed.Results: The postoperative BCVA increased by 93.8% (15/16 eyes) and 77.2% (27/36 eyes) at the one-year follow-up in the DLKP and PKP groups, respectively: the differences were not statistically significant (p=0.149). The therapeutic success rates did not differ (statistically) significantly between the DLKP (81.2%) and PKP (80.6%) groups (p=0.953). The incidence of secondary glaucoma was 6.25% and 33.33% in the DLKP and PKP groups, respectively, and the difference between them was statistically significant (p=0.037). The graft survival rates at the one-year follow-up differed significantly between the DLKP (12.5%) and PKP (42.9%) groups (p=0.033).Conclusion: Infectious keratitis is common in male farmers in northern China. Therapeutic keratoplasty is the most commonly performed vision-saving procedure for patients with severe serious infectious keratitis, which can improve the quality of life significantly. Bandage contact lenses were commonly used to protect the cornea and ameliorate pain. DLKP and PKP elicited good clinical outcomes with respect to visual recovery and therapeutic success. The frequencies of graft rejection and complications were lower with DLKP compared to PKP. Surgery should be considered at the early stage in patients with refractory infectious keratitis to improve the therapeutic success.

show abstract

“…No significant differences in visual acuity and macular anatomy were observed between the two anti-VEGF drugs. Aflibercept (Eylea; Regeneron, Inc., Tarrytown, NJ, USA) and conbercept (Langmu; Kanghong, Inc., Sichuan, China) belong to the fusion protein anti-VEGF group of drugs and have a strong affinity for VEGF-A, VEGF-B, and PlGF [28] . In the MYRROR trial [29] , an international, phase III, multicentre, randomised, double-blind and sham-controlled study, 122 patients with PM-CNV were randomly divided into the treatment group (91 cases) and sham treatment group (31 cases).…”

Section: Conbercept In the Treatment Of Choroidal Neovascularizationmentioning

confidence: 99%

Long-term clinical effects of intravitreal injections of conbercept for the treatment of choroidal neovascularization in patients with pathological myopia

Zhang¹,

Chen²,

Zhang³

et al. 2022

Int J Ophthalmol

View full text Add to dashboard Cite

AIM: To observe the long-term clinical efficacy of intravitreal injections of conbercept, a novel vascular growth factor inhibitor, for the treatment of pathological myopia choroidal neovascularization (PM-CNV). METHODS: A total of 67 eyes (from 67 patients; mean age, 54.90±12.7y) with PM-CNV were retrospectively researched. Based on the different schemes used for the administration of the drug, the patients were divided into two groups: group A (n=35; average age, 53.31±13.6y; average diopter, 9.25±1.72 D), which received only one injection of pro re nata (PRN; 1+PRN regimen), and group B (n=32; average age, 56.49±11.8y; average diopter, 9.63±2.24 D), which received one injection per month for 3mo (3+PRN regimen). Best-corrected visual acuity (BCVA) analysis, intraocular pressure (IOP) examination, slit-lamp microscopy, fundus examination and optical coherence tomography were performed at each follow-up. The recurrence and treatment times of CNV were recorded. The patients were followed up for at least 12mo. RESULTS: The BCVA was increased in 29 eyes (82.9%) in group A and 30 eyes (93.75%) in group B; no increase or decrease was observed in 6 (17.1%) and 2 (6.25%) eyes in groups A and B, respectively. The BCVA (logMAR) values before treatment (0.67±0.48 and 0.71±0.56) were significantly higher than those 12mo after treatment (0.31±0.26 and 0.33±0.17) in groups A and B, respectively (P<0.05). The mean central macular thickness (CMT) values had significantly decreased from 346.49±65.99 and 360.10±82.31 μm at baseline to 257.29±40.47 and 251.97±48.26 μm in groups A and B, respectively, after 12mo of treatment. A total of 21 eyes in group A needed reinjection (60%; average number of injections, 2.51±0.98); the corresponding values in group B were 6 eyes (18.75%; average number of injections, 3.74±1.22). There were no adverse ocular and systemic complications during the treatment and follow-up. CONCLUSION: Intravitreal injection of conbercept with 1+PRN or 3+PRN improve the visual acuity, reduce macular edema and reduce the level of CMT in patients with PM-CNV. The 3+PRN regimen demonstrates a lower recurrence rate of CNV than the 1+PRN regimen, but requires more treatment. However, both treatment regimens demonstrate long-term safety and efficacy for the treatment of PM-CNV.

show abstract

Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept

Cited by 8 publications

References 118 publications

Obstructive Sleep Apnea is Related with the Risk of Retinal Vein Occlusion

Obstructive Sleep Apnea is Related with the Risk of Retinal Vein Occlusion

Clinical Observation of Therapeutic Keratoplasties for Infectious Keratitis: A Retrospective Cohort Study

Long-term clinical effects of intravitreal injections of conbercept for the treatment of choroidal neovascularization in patients with pathological myopia

Contact Info

Product

Resources

About